MaxCyte, Inc.
NASDAQ•MXCT
CEO: Mr. Maher Masoud
板块: Healthcare
行业: Medical - Devices
上市日期: 2021-07-30
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
联系方式
市值
$89.14M
市盈率 (TTM)
-1.9
30
股息率
--
52周最高
$3.58
52周最低
$0.64
52周范围
排名55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
疲弱 • 2.6 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025
财务仪表盘
Q3 2025 数据
营业收入
$6.83M-16.35%
近4季度走势
每股收益
-$0.12+9.09%
近4季度走势
自由现金流
-$7.76M+61.73%
近4季度走势
2025 Q3 财报亮点
核心亮点
Q3 Revenue Decline Total revenue $6.83M USD for Q3 2025, a 16% decrease versus Q3 2024, driven primarily by core sales contraction.
SPL Revenue Volatility Nine months SPL program revenue $2.88M USD, falling 52% due to uncertain achievement timing of clinical milestones.
SeQure Acquisition Finalized Acquired SeQure in January 2025; preliminary goodwill recorded at $3.55M USD following purchase price allocation adjustments.
Increased Operating Burn Net cash used in operating activities totaled $31.72M USD for nine months, significantly higher than the prior year period.
关注风险
Widening Net Loss Nine months net loss reached $(35.03M) USD, increasing from $(30.46M) USD in 2024 due to lower revenue.
Cash Position Decline Cash and equivalents decreased to $12.97M USD by September 30, 2025, reflecting increased operating cash burn.
Restructuring Execution Costs Implemented 34% workforce reduction plan, incurring $3.06M USD restructuring expense during the third quarter period.
Customer Concentration Risk One customer accounted for 51% of total accounts receivable as of September 30, 2025, posing significant concentration risk.
前瞻展望
Liquidity Runway Secured Existing cash resources expected to fund operating expenses and capital needs for at least the next 12 months.
Strategic Cost Alignment Workforce reduction plan targets 34% reduction to streamline operations and align resources with strategic priorities.
Future Revenue Expectation Expect total revenue growth as customer programs advance, driven by instrument sales and expanding SPL base.
Continued R&D Investment Expect substantial research and development expenses to support customers and develop new product offerings going forward.
同行对比
营业收入 (TTM)
$445.38M
$105.66M
$95.11M
毛利率 (最新季度)
100.0%
92.4%
87.3%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| ARMP | $399.02M | -8.5 | 70.3% | 198.5% |
| FBRX | $379.31M | -10.4 | -75.6% | 0.0% |
| CATX | $379.04M | -3.6 | -39.1% | 1.1% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
-7.7%
增长承压
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
0%
现金流需要关注
深度研究
下次财报:2026年3月10日
每股收益:-$0.08
|营业收入:$9.16M
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据